Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Insilico’s AI-discovered INS018_055 graduates to phase 2

By Brian Buntz | June 27, 2023

Insilico MedicineRoughly a year ago, Insilico Medicine announced that it had dosed the first patient in a phase 1 study of INS018_055, an AI-discovered, first-in-class small molecule inhibitor. Now, the company has progressed to the next stage, launching a phase 2 study for the drug candidate.

Insilico, a founding member of NVIDIA Inception, developed its AI drug-discovery platform on NVIDIA GPUs. Inception is a complimentary program that provides startups with technical training and AI platform support.

The discovery of INS018_055 was the result of combining multiple technologies. Insilico’s proprietary Pharma.AI platform incorporates AI models trained on massive amounts of data. Insilico’s target identification platform, PandaOmics, discovered a novel target. Then Insilico’s generative chemistry platform, Chemistry42, designed the molecule’s structure. In addition, these AI systems rely on machine learning techniques like deep generative models, reinforcement learning and transformers. Insilico uses these techniques to discover new targets and generate new molecular structures.

For more information on the story behind INS018_055, check out our interview with the company’s CEO, Alex Zhavoronkov.

Navigating AI-driven drug discovery: Insilico’s path to phase 2

Here are the key details about the progress and design of INS018_055:

  • Role of AI: Insilico discovered and designed INS018_055 with generative AI.
  • Drug features: The company describes INS018_055 as an anti-fibrotic small molecule inhibitor, with both the target and molecular structure identified through AI methods.
  • Phase 1 results: The drug candidate received positive topline data in Phase I trials, and was tested in 78 and 48 healthy subjects in New Zealand and China, respectively.
  • Regulatory traction: The drug candidate received FDA Orphan Drug Designation in early 2023, which refers to its potential to treat a rare disease (in this case, Idiopathic Pulmonary Fibrosis or IPF).
  • Phase 2 study design: The phase 2 trials are randomized, double-blind, placebo-controlled trials, a gold standard in clinical trial design. They aim to assess safety, tolerability, pharmacokinetics and preliminary efficacy.

In all, Insilico has a growing pipeline comprising more than 30 programs.

The role of AI-driven drug discovery in the development of INS018_055

Earlier this year, the company announced that it was involved in research employing DeepMind’s deep learning-driven AlphaFold protein structure database to design and synthesize a potential hepatocellular carcinoma (HCC) drug in only 30 days. In May, it also won IND approval for an AI-designed USP1 inhibitor for cancer trials in U.S. and China.

At present, there are only two FDA-approved drugs available for IPF, including Ofev (nintedanib) from Boehringer Ingelheim and Esbriet (pirfenidone) from Genentech. Last year, launched its phase 3 FIBRONEER-IPF study for BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor for IPF.


Filed Under: clinical trials, Data science, Drug Discovery, machine learning and AI, Pulmonology, Rare disease
Tagged With: AI in Pharma, Idiopathic pulmonary fibrosis, Insilico Medicine, nvidia inception, orphan drug designation, phase 2 trials, small molecule inhibitors
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

FDA’s genAI push could save CDER hundreds of thousands of review hours annually
Elsevier plugs 500,000 ClinicalTrials.gov records into Embase
Transparent padlock, digital security concept, glowing background. AI generated
The challenge of AI inventorship in healthcare
From Graz to global — Innophore’s journey with NVIDIA’s BioNeMo
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE